The CANnabinoids in CANcer (CANCAN) trial: Investigating the effect of medicinal cannabis on symptoms and side effects of chemotherapy in people with cancer

Central Adelaide Local Health Network (CALHN)0 个研究点目标入组 176 人开始时间: 2022年3月11日最近更新: 2022年3月21日

研究概览

暂无简介。

•18 years of age or older
•Scheduled to receive mucotoxic, systemic cancer therapy for advanced solid and haematological cancers.
•Anticipated to undergo 3 cycles of chemotherapy (solid tumour cancer participants) OR autologous stem cell transplantation (haematological cancers – HSCT participants).
•Willing to commit to not taking cannabis in any other form during the clinical trial period.
•For randomisation of solid tumour participants: Gut distress symptoms related to their cancer therapy defined by a score of greater or equal to 1 in the MDQ and confirmed by research nurse.

•Cannabis dependence / misuse defined by the revised Cannabis Use Disorder Identification test score of 8 or above.
•History of unstable cardiovascular disease including myocardial infarction or cerebrovascular accident, crescendo history of angina or heart failure.
•Recreational or medicinal cannabis use defined as use >once/week in the month leading up to the clinical trial period.
•History of psychosis secondary to, or intolerance to cannabis products.
•Presence of an active psychiatric disorder or concurrent disorder that may be exacerbated by
•cannabinoids, or which may interfere with clinical trial outcome determination (determined by the recruiting clinician).
•Pregnant or planning on becoming pregnant.
•Currently lactating.
•Involved in another clinical trial (except observational trials) or expected to start one soon after completion.
•Pre-existing oral disease or disability that would impair oral-administration or mucosal absorption.
•Presence of known impairment of hepatic synthetic dysfunction.
•Laboratory values suggestive of liver dysfunction.

发起方

Central Adelaide Local Health Network (CALHN)